Everest acquires Firma’s biometrics and data services unit
Everest Clinical Research has acquired Firma Clinical Research's biometrics and data services business unit, Firma DS, for an undisclosed sum.…
All articles by Salong Debbarma
Salong Debbarma
-
-
China’s NMPA clears Akeso’s AK158D1 for Phase I trial in solid tumours
Akeso has received clearance from the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA) to begin…
-
Optimi Health plans Phase III trial of PTSD therapy
Optimi Health is set to initiate a Phase III clinical trial to assess methylenedioxymethamphetamine (MDMA)-assisted therapy to treat individuals living…
-
SpliSense begins Phase IIb SPL84 trial for cystic fibrosis
SpliSense has commenced a Phase IIb clinical trial of its inhaled antisense oligonucleotide therapy, SPL84, in people with cystic fibrosis…
-
Syntis Bio announces Phase I/Ib data for SYNT-101 in obesity
Syntis Bio has reported results from the multiple ascending dose (MAD) segment of its Phase I/Ib SYNTIETY-1 trial of SYNT-101,…
-
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Arrowhead Pharmaceuticals has reported interim top-line results from an ongoing Phase I/IIa clinical trial investigating ARO-DIMER-PA to treat mixed hyperlipidaemia.…
-
BioNTech and OncoC4 report median OS data from RESERVE-003 Phase III trial
BioNTech and OncoC4 have reported the initial median overall survival (OS) results from the PRESERVE-003 Phase III trial’s non-pivotal stage…
-
Taiho, Cullinan report improved PFS in Phase III NSCLC trial
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics have reported results from the Phase III REZILIENT3 trial, showing that zipalertinib combined…
-
TenNor reports top-line Phase IIa results for rifaquizinone in PJI
TenNor Therapeutics has reported positive top-line data from a Phase IIa trial assessing its drug candidate, rifaquizinone (TNP-2092), in patients…
-
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody, which…